Sarah Gheuens sold $296K of Agios Pharmaceuticals stock
By AlphaYouPublished Form 4
Gheuens Sarah
Reporting filer
Sarah Gheuens reported selling 7,866 shares of Agios Pharmaceuticals, Inc. for about $296K ($37.69 a share on average). Form 4 filed Oct 28, 2026 lists 3 entries.
See the price move since this trade →
- Disclosed
- Oct 28, 2026
Reported details
3 entries| Security | Owner | Date | Code | Action | Quantity | Price | Following holdings | Reporting delay | Filed terms and references |
|---|---|---|---|---|---|---|---|---|---|
| Common stock | Gheuens Sarah | 2026-10-26 | M | Exercise or conversion | 7866 | 25.01 | 62,511 | 2 days | Filed terms
|
| Common stock | Gheuens Sarah | 2026-10-26 | S | Sale | 7866 | 37.69 | 54,645 | 2 days | Filed terms
|
| Stock options (right to buy) (derivative) | Gheuens Sarah | 2026-10-26 | M | Exercise or conversion | 7866 | 0 | 16,275 | 2 days | Filed terms
|
Common stock
- Owner
- Gheuens Sarah
- Date
- 2026-10-26
- Code
- M
- Action
- Exercise or conversion
- Quantity
- 7866
- Price
- 25.01
- Following holdings
- 62,511
- Reporting delay
- 2 days
- Filed terms and references
Filed terms
- security Title: Common stock
- transaction Date: 2026-10-26
- transaction Form Type: 4
- transaction Code: M
- equity Swap Involved: 0
- transaction Shares: 7866
- transaction Price Per Share: 25.01
- transaction Acquired Disposed Code: A
- shares Owned Following Transaction: 62511
- direct Or Indirect Ownership: D
Common stock
- Owner
- Gheuens Sarah
- Date
- 2026-10-26
- Code
- S
- Action
- Sale
- Quantity
- 7866
- Price
- 37.69
- Following holdings
- 54,645
- Reporting delay
- 2 days
- Filed terms and references
Filed terms
- security Title: Common stock
- transaction Date: 2026-10-26
- transaction Form Type: 4
- transaction Code: S
- equity Swap Involved: 0
- id: F1
- transaction Shares: 7866
- transaction Price Per Share: 37.69
- id: F2
- transaction Acquired Disposed Code: D
- shares Owned Following Transaction: 54645
- direct Or Indirect Ownership: D
Stock options (right to buy) (derivative)
- Owner
- Gheuens Sarah
- Date
- 2026-10-26
- Code
- M
- Action
- Exercise or conversion
- Quantity
- 7866
- Price
- 0
- Following holdings
- 16,275
- Reporting delay
- 2 days
- Filed terms and references
Filed terms
- security Title: Stock options (right to buy)
- conversion Or Exercise Price: 25.01
- transaction Date: 2026-10-26
- transaction Form Type: 4
- transaction Code: M
- equity Swap Involved: 0
- transaction Shares: 7866
- transaction Price Per Share: 0
- transaction Acquired Disposed Code: D
- id: F3
- expiration Date: 2033-03-01
- underlying Security Title: Common stock
- underlying Security Shares: 7866
- shares Owned Following Transaction: 16275
- direct Or Indirect Ownership: D
Purchases, sales, grants and option exercises are different transactions. The reported code identifies the action; it does not establish a motive.
Filing context
- Quantities and prices are shown in the units filed. No trade value is inferred from their product.
- Gheuens Sarah: Chief Medical Officer.
- The filing reports a Rule 10b5-1 trading plan.
- F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F2: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $37.53 to $38.06. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F3: This option was granted on March 1, 2023. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2024, with the remaining 75% vesting in 36 equal monthly installments thereafter.
Original sources
Prepared automatically from public filing data. Report a correction.